The Defense Health Agency awarded a $1,397,266 project grant to The University of Queensland under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from March 1, 2023 through February 28, 2026 to develop peptide inhibitors targeting sodium channels for the treatment of Amyotrophic Lateral Sclerosis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care through innovative research and investigating medical solutions for battlefield medicine. This award will further those goals by supporting the grantee's research into developing new therapeutic targets for ALS.
Generated 1/6/24, 10:57 AM